You are here: Industry Insights > trial

News List

Purdue Pharma prepares for bankruptcy ahead of opioid crisis trial europeanpharmaceuticalreview
September 06, 2019
A report has found that the rejection of a settlement offer from Purdue has led to the company arranging to file for bankruptcy.
Infinity Announces Start of Two IPI-549 Trials for Solid Tumors americanpharmaceuticalreview
September 05, 2019
Infinity Pharmaceuticals announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through ...
Impel NeuroPharma Announces Last Patient Enrolled in INP104 Trial for Migraine americanpharmaceuticalreview
September 05, 2019
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use...
VenatoRx Initiates Enrollment of Cefepime/VNRX-5133 Phase 3 Trial americanpharmaceuticalreview
September 03, 2019
VenatoRx Pharmaceuticals has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).
Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI americanpharmaceuticalreview
September 03, 2019
Acurx Pharmaceuticals announced its lead product candidate, ACX-362E, has successfully completed the 68-subject, double-blind, placebo-controlled, multiple-ascending dose Phase 1 clinical trial of ACX-362E in healthy volunteers.
Men Should Be Included in Breast Cancer Clinical Trials drugs
August 27, 2019
Men should be included in clinical trials of new breast cancer treatments, the U.S. Food and Drug Administration says.
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol drugs
August 16, 2019
Regeneron Pharmaceuticals, Inc. today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody...
Chlamydia vaccine passes safety trial europeanpharmaceuticalreview
August 15, 2019
A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response.
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial drugs
August 15, 2019
Kala Pharmaceuticals, Inc. announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s new drug application (NDA) for...
Ebola clinical trial stopped early due to positive results europeanpharmaceuticalreview
August 14, 2019
An Ebola clinical trial has been stopped early as Regeneron’s REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page